PMC8548719_01
The chest CT of patient one. (A-D): chest CT showing the nodes in the lungs and the local grid change in the right lower lobe. (E-H): chest CT showing the pneumonitis 74 days after afatinib therapy, the pneumonitis manifested subpleural reticular shadow, ground glass and consolidation, and beehives, distributed in both lower lobe of both lungs. CT: computed tomography.
fphar-12-698447-g001.jpg
PMC8548719_01_fphar-12-698447-g001.jpg
F1
Figures 1A-D shows the patient's lung lesions at partial response, and Figures 1E-H shows the lung inflammation.
The episodes occurred in case 1.
fphar-12-698447-g002.jpg
PMC8548719_01_fphar-12-698447-g002.jpg
F2
Figure 2 showed the episodes according to the order of occurrence for case 1.
PMC8548719_02
The chest CT of patient two. (A-D): chest CT showing the lung quality before afatinib. (E-H): chest CT showing pneumonia 27 days after afatinib therapy, the grid changes and ground glass hinting on lung injury. (I-L): chest CT 5 days after discontinuation of afatinib and empirical antibiotics, showing enlarged field of grid changes and pulmonary interstitial edema, indicating the diffused alveolar injury. (M-P): chest CT 17 days after glucocorticoid therapy, the grid changes and pulmonary interstitial edema reduced significantly, indicating improvements of lung injury. CT: computed tomography.
fphar-12-698447-g003.jpg
PMC8548719_02_fphar-12-698447-g003.jpg
F3
Figures 3A-D showed there was no inflammation in the lungs before afatinib. Figures 3E-H showed multiple patches and grid shadows were seen on both sides of the lung. CT showed a larger range of lung inflammation (Figures 3I-L). Figures 3M-P shows lung inflammation 17 days after the first dose of methylprednisolone.
The episodes occurred in case 2.
fphar-12-698447-g004.jpg
PMC8548719_02_fphar-12-698447-g004.jpg
F4
Figure 4 showed the episodes according to the order of occurrence for case 2.